Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sodium–Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies
Thomas M. Caparrotta, Andrew M. Greenhalgh, Karen Osinski, et al.
Diabetes Therapy (2021) Vol. 12, Iss. 4, pp. 991-1028
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Novel Antidiabetic Drugs and Risk of Venous Thromboembolism: A Literature Review
Qingui Chen, Rayna J.S. Anijs, Judith P.L. Verlaan, et al.
Seminars in Thrombosis and Hemostasis (2025)
Closed Access | Times Cited: 1
SGLT-2 Inhibitors and the Inflammasome: What’s Next in the 21st Century?
Dimitris Kounatidis, Natalia G. Vallianou, Angelos Evangelopoulos, et al.
Nutrients (2023) Vol. 15, Iss. 10, pp. 2294-2294
Open Access | Times Cited: 21
SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review
Merlin C. Thomas, Brendon L. Neuen, Stephen M. Twigg, et al.
Endocrine Connections (2023) Vol. 12, Iss. 8
Open Access | Times Cited: 15
Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS
Xiang Zhou, Xiaofei Ye, Xiaojing Guo, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 32
Comparative Genitourinary Safety of In-class Sodium-Glucose Cotransporter-2 Inhibitors among Patients with Heart Failure with Preserved Ejection Fraction: A Cohort Study
Munaza Riaz, Jingchuan Guo, Steven M. Smith, et al.
American Journal of Cardiovascular Drugs (2024) Vol. 24, Iss. 3, pp. 455-464
Closed Access | Times Cited: 4
Cardiovascular Outcomes of Patients With Type 2 Diabetes With Urinary Tract Infection Post Sodium-Glucose Cotransporter 2 Inhibitors Treatment: A Multicenter Observational Study
T Hsu, Feng-Hsuan Liu, Jui‐Hung Sun, et al.
Endocrine Practice (2025)
Open Access
Multimodality imaging approach to left ventricular dysfunction in diabetes: an expert consensus document from the European Association of Cardiovascular Imaging
Thomas H. Marwick, Alessia Gimelli, Sven Plein, et al.
European Heart Journal - Cardiovascular Imaging (2021) Vol. 23, Iss. 2, pp. e62-e84
Open Access | Times Cited: 25
Management of Type 2 Diabetic Kidney Disease in 2022: A Narrative Review for Specialists and Primary Care
David Z.I. Cherney, Alan Bell, Louis Girard, et al.
Canadian Journal of Kidney Health and Disease (2023) Vol. 10
Open Access | Times Cited: 10
SGLT -2 Inhibitors and the Inflammasome: What's next in the 21st century?
Dimitris Kounatidis, Natalia G. Vallianou, Angelos Evangelopoulos, et al.
(2023)
Open Access | Times Cited: 10
Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies
Chun Xing Li, Tian Tian Liu, Qian Zhang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 10
Prevalence of sodium-glucose transporter 2 inhibitor-associated diabetic ketoacidosis in real-world data: A systematic review and meta-analysis
Bassel Al-Hindi, Mohammed A. Mohammed, Ernest Mangantig, et al.
Journal of the American Pharmacists Association (2023) Vol. 64, Iss. 1, pp. 9-26.e6
Closed Access | Times Cited: 9
Risk of Urogenital Bacterial Infection with Sodium-Glucose Cotransporter-2 Inhibitors: A Retrospective Cohort Study Using a Claims Database
Takanori Imai, Naoto Kato, Naoki Kanda, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 8, pp. 1821-1830
Open Access | Times Cited: 3
SGLT2 inhibition in heart failure with reduced or preserved ejection fraction: Finding the right patients to treat
Nicolas Girerd, Faı̈ez Zannad
Journal of Internal Medicine (2023) Vol. 293, Iss. 5, pp. 550-558
Open Access | Times Cited: 8
Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials
Asif Muhammed, Christy Thomas, Vivekanandan Kalaiselvan, et al.
Expert Opinion on Drug Safety (2023) Vol. 23, Iss. 6, pp. 731-742
Closed Access | Times Cited: 7
Acute renal injury events in diabetic patients treated with SGLT2 inhibitors: A comprehensive review with a special reference to RAAS blockers
André Scheen, Pierre Delanaye
Diabetes & Metabolism (2021) Vol. 48, Iss. 2, pp. 101315-101315
Closed Access | Times Cited: 17
Key results from observational studies and real‐world evidence of sodium‐glucose cotransporter‐2 inhibitor effectiveness and safety in reducing cardio‐renal risk
Thomas Nyström
Diabetes Obesity and Metabolism (2024)
Open Access | Times Cited: 2
The Outcomes of Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2I) on Diabetes-Associated Neuropathy: A Systematic Review and meta-Analysis
Mahmoud Kandeel
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 9
Safety outcomes of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and other risk factors for cardiovascular disease: a systematic review and meta-analysis
Radhika Deshpande, Raj Patel, Manjari Rani Regmi, et al.
Cardiovascular Endocrinology & Metabolism (2023) Vol. 12, Iss. 2
Open Access | Times Cited: 5
Cardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients
Xiutian Chen, Jiali Wang, Yongda Lin, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 5
SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction
Tripti Rastogi, Nicolas Girerd
Heart Failure Clinics (2022) Vol. 18, Iss. 4, pp. 561-577
Open Access | Times Cited: 8
Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors among patients with heart failure with preserved ejection fraction
Munaza Riaz, Steven M. Smith, Eric Dietrich, et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2023) Vol. 43, Iss. 10, pp. 1024-1031
Closed Access | Times Cited: 4
A retrospective study of seasonal variation in sodium-glucose co-transporter 2 inhibitor-related adverse events using the Japanese adverse drug event report database
Kiyoka Matsumoto, Fumiya Goto, Mika Maezawa, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
Natalia G. Vallianou, Gerasimos Socrates Christodoulatos, Dimitris Kounatidis, et al.
Metabolism Open (2021) Vol. 10, pp. 100089-100089
Open Access | Times Cited: 10
Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes
Ai‐Yu Yang, Hung‐Chun Chen
Journal of Diabetes Research (2022) Vol. 2022, pp. 1-10
Open Access | Times Cited: 6
Epidemiology of acute kidney injury adverse events with SGLT2 inhibitors: A meta-analysis of observational cohort studies
Pierre Delanaye, André Scheen
Diabetes Epidemiology and Management (2021) Vol. 3, pp. 100021-100021
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top